Senores Pharmaceuticals (SPL), through its wholly-owned US subsidiary Senores Pharmaceuticals, USA (SPI), has signed an agreement to acquire two USFDA-approved Abbreviated New Drug Applications (ANDAs) from Teva Pharmaceuticals USA.

According to market estimates, the acquired products represent an addressable opportunity of approximately USD 38 million in the US market for the 12 months ending December 2024, based on IQVIA data, and around USD 120 million for the 12 months ending June 2025, as per speciality data provider Symphony.

The acquisition will be funded from the proceeds of SPL’s Initial Public Offer, in line with the objectives outlined in its Red Herring Prospectus.